207 related articles for article (PubMed ID: 20518582)
41. Letter to the Editor on Cross-Protection of RotaTeq.
Carias C; Hartwig S; Kanibir N; Matthijnssens J; Tu Y
J Pediatr; 2024 May; 268():113952. PubMed ID: 38336206
[No Abstract] [Full Text] [Related]
42. Rotavirus vaccine withdrawal in the United states; the role of postmarketing surveillance.
Delage G
Can J Infect Dis; 2000 Jan; 11(1):10-2. PubMed ID: 18159257
[No Abstract] [Full Text] [Related]
43. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
Soares-Weiser K; Maclehose H; Bergman H; Ben-Aharon I; Nagpal S; Goldberg E; Pitan F; Cunliffe N
Cochrane Database Syst Rev; 2012 Nov; 11():CD008521. PubMed ID: 23152260
[TBL] [Abstract][Full Text] [Related]
44. Intussusception risk after rotavirus vaccination in U.S. infants.
Yih WK; Lieu TA; Kulldorff M; Martin D; McMahill-Walraven CN; Platt R; Selvam N; Selvan M; Lee GM; Nguyen M
N Engl J Med; 2014 Feb; 370(6):503-12. PubMed ID: 24422676
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of Rotavirus Vaccination: A Systematic Review of the First Decade of Global Postlicensure Data, 2006-2016.
Jonesteller CL; Burnett E; Yen C; Tate JE; Parashar UD
Clin Infect Dis; 2017 Sep; 65(5):840-850. PubMed ID: 28444323
[TBL] [Abstract][Full Text] [Related]
46. Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine.
Goveia MG; Ciarlet M; Owen KE; Ranucci CS
Ann N Y Acad Sci; 2011 Mar; 1222():14-8. PubMed ID: 21434938
[TBL] [Abstract][Full Text] [Related]
47. Rotavirus.
Esona MD; Gautam R
Clin Lab Med; 2015 Jun; 35(2):363-91. PubMed ID: 26004648
[TBL] [Abstract][Full Text] [Related]
48. Rotavirus vaccine efficacy: current status and areas for improvement.
Carvalho MF; Gill D
Hum Vaccin Immunother; 2019; 15(6):1237-1250. PubMed ID: 30215578
[TBL] [Abstract][Full Text] [Related]
49. A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact.
Pindyck T; Tate JE; Parashar UD
Expert Rev Vaccines; 2018 Jul; 17(7):593-606. PubMed ID: 29909693
[TBL] [Abstract][Full Text] [Related]
50. Impact of vaccination with different types of rotavirus vaccines on the incidence of intussusception: a randomized controlled meta-analysis.
Wang G; Zhang K; Zhang R; Kong X; Guo C
Front Pediatr; 2023; 11():1239423. PubMed ID: 37583623
[TBL] [Abstract][Full Text] [Related]
51. Structural basis of P[II] rotavirus evolution and host ranges under selection of histo-blood group antigens.
Xu S; McGinnis KR; Liu Y; Huang P; Tan M; Stuckert MR; Burnside RE; Jacob EG; Ni S; Jiang X; Kennedy MA
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34475219
[TBL] [Abstract][Full Text] [Related]
52. Prevalence and genotype distribution of group A rotavirus circulating in Shanxi Province, China during 2015-2019.
Zhao L; Shi X; Meng D; Guo J; Li Y; Liang L; Guo X; Tao R; Zhang X; Gao R; Gao L; Wang J
BMC Infect Dis; 2021 Jan; 21(1):94. PubMed ID: 33478417
[TBL] [Abstract][Full Text] [Related]
53. Increasing detection of rotavirus G2P[4] strains in Nizhny Novgorod, Russia, between 2016 and 2019.
Morozova OV; Sashina TA; Epifanova NV; Kashnikov AY; Novikova NA
Arch Virol; 2021 Jan; 166(1):115-124. PubMed ID: 33079276
[TBL] [Abstract][Full Text] [Related]
54. Current status of rotavirus vaccines.
Wang CM; Chen SC; Chen KT
World J Pediatr; 2015 Nov; 11(4):300-8. PubMed ID: 26454434
[TBL] [Abstract][Full Text] [Related]
55. The first case of Kawasaki disease in a 20-month old baby following immunization with rotavirus vaccine and hepatitis A vaccine in China: A case report.
Yin S; Liubao P; Chongqing T; Xiaomin W
Hum Vaccin Immunother; 2015; 11(11):2740-3. PubMed ID: 26158590
[TBL] [Abstract][Full Text] [Related]
56. Decline in rotavirus hospitalizations following the first three years of vaccination in Castile-La Mancha, Spain.
Redondo O; Cano R; Simón L
Hum Vaccin Immunother; 2015; 11(3):769-75. PubMed ID: 25644531
[TBL] [Abstract][Full Text] [Related]
57. Disease caused by rotavirus infection.
Lin CL; Chen SC; Liu SY; Chen KT
Open Virol J; 2014; 8():14-9. PubMed ID: 25553142
[TBL] [Abstract][Full Text] [Related]
58. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries.
Plosker GL
Drugs R D; 2012 Dec; 12(4):239-44. PubMed ID: 23017130
[TBL] [Abstract][Full Text] [Related]
59. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries.
Plosker GL
Paediatr Drugs; 2012 Dec; 14(6):429-33. PubMed ID: 23013458
[TBL] [Abstract][Full Text] [Related]
60. Costs of gastroenteritis in the Netherlands, with special attention for severe cases.
Friesema IH; Lugnér AK; van Duynhoven YT;
Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1895-900. PubMed ID: 22228374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
